Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fritz Leutmezer

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Epileptic Disorders : International Epilepsy Journal with Videotape|April 23, 2002
Postictal signs of lateralizing and localizing significanceFritz Leutmezer, Christoph Baumgartner
Epilepsia|October 9, 2002
Serum s-100 protein is not a suitable seizure marker in temporal lobe epilepsyFritz Leutmezer, Oswald Wagner, Christoph Baumgartner
Brain and Behavior|March 19, 2023
Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in AustriaMichael Guger, Robert Hatschenberger, Fritz Leutmezer
Epilepsy Research|August 30, 2002
Focal features in patients with idiopathic generalized epilepsyFritz Leutmezer, Stefanie Lurger, Christoph Baumgartner
Epilepsia|March 5, 2003
Electrocardiographic changes at the onset of epileptic seizuresFritz Leutmezer, Christiana Schernthaner, Stefanie Lurger, et al.
Journal of Neurology|April 5, 2020
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting methodMichael Guger, Christian Enzinger, Fritz Leutmezer, et al.
The Tohoku Journal of Experimental Medicine|January 9, 2015
Elevated levels of carbonyl proteins in cerebrospinal fluid of patients with neurodegenerative diseasesPaulus S Rommer, Joachim Greilberger, Sabine Salhofer-Polanyi, et al.
Journal of Neurology|July 18, 2019
Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment RegistryMichael Guger, Christian Enzinger, Fritz Leutmezer, et al.
Journal of Neurology|September 19, 2019
Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment RegistryMichael Guger, Christian Enzinger, Fritz Leutmezer, et al.
Acta Neurologica Scandinavica|April 9, 2019
Real-life use of oral disease-modifying treatments in AustriaMichael Guger, Christian Enzinger, Fritz Leutmezer, et al.
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Epileptic Disorders : International Epilepsy Journal with Videotape|April 23, 2002
Postictal signs of lateralizing and localizing significanceFritz Leutmezer, Christoph Baumgartner
Epilepsia|October 9, 2002
Serum s-100 protein is not a suitable seizure marker in temporal lobe epilepsyFritz Leutmezer, Oswald Wagner, Christoph Baumgartner
Brain and Behavior|March 19, 2023
Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in AustriaMichael Guger, Robert Hatschenberger, Fritz Leutmezer
Epilepsy Research|August 30, 2002
Focal features in patients with idiopathic generalized epilepsyFritz Leutmezer, Stefanie Lurger, Christoph Baumgartner
Epilepsia|March 5, 2003
Electrocardiographic changes at the onset of epileptic seizuresFritz Leutmezer, Christiana Schernthaner, Stefanie Lurger, et al.
Journal of Neurology|April 5, 2020
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting methodMichael Guger, Christian Enzinger, Fritz Leutmezer, et al.
The Tohoku Journal of Experimental Medicine|January 9, 2015
Elevated levels of carbonyl proteins in cerebrospinal fluid of patients with neurodegenerative diseasesPaulus S Rommer, Joachim Greilberger, Sabine Salhofer-Polanyi, et al.
Journal of Neurology|July 18, 2019
Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment RegistryMichael Guger, Christian Enzinger, Fritz Leutmezer, et al.
Journal of Neurology|September 19, 2019
Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment RegistryMichael Guger, Christian Enzinger, Fritz Leutmezer, et al.
Acta Neurologica Scandinavica|April 9, 2019
Real-life use of oral disease-modifying treatments in AustriaMichael Guger, Christian Enzinger, Fritz Leutmezer, et al.
Pageof 12